Cart
sales@molnova.com
Lirilumab
CAS No. 1000676-41-4
Lirilumab( —— )
Catalog No. M36889 CAS No. 1000676-41-4
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 440 | In Stock |
|
| 10MG | 692 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1376 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLirilumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
-
DescriptionLirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
-
In Vitro——
-
In VivoLirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells Dosage:15 mg/kg Administration:intravenous injection; 15 mg/kg; once Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorVirus Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1000676-41-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.?
molnova catalog
related products
-
CL 277082
CL 277082 (Ddpmhu) is an acyl coenzyme A:cholesterol O-acyltransferase inhibitor that inhibits granuloma tissue ACAT activity.
-
Emodin 6-O-β-D-gluco...
Emodin 6-O-β-D-glucoside can protect barrier integrity and inhibit HMGB1-mediated inflammatory responses, which suggests a potential use as a therapy for sepsis or septic shock.
-
AB-680
AB-680 is a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity.
